PerkinElmer acquires Labtronics, buyouts pile up

PerkinElmer's ($PKI) software company buying spree continues. The Waltham, MA-based life sciences products and services firm said today that it has bought Ontario, Canada-based electronic laboratory notebook provider Labtronics. This deal follows PerkinElmer's buyout earlier this month of genomic analysis software firm Geospiza and its purchases of a pair of informatics firms in March.

While PerkinElmer didn't disclose how much it's paying for Labtronics, the buyer said that the Labtronics purchase brings it the ability to extend its electronic lab notebook and data integration software product offerings. The products are used for regulated and non-regulated quality control as well as late-stage product testing or method development labs, according to PerkinElmer.

PerkinElmer is investing in boosting its ability to serve the data analysis and management needs of all sorts of life sciences customers. With its purchase of Geospiza early this month, PerkinElmer boosted its ability to help labs that are conducting genomics research and DNA sequencing to manage and analyze large amounts of genomic data. In March, PerkinElmer said it would buy informatics companies CambridgeSoft and ArtusLabs for a combined sum of $220 million.

"We welcome the addition of Labtronics to PerkinElmer's growing portfolio of informatics and software solutions for laboratory environments, as we enhance the Company's strategic focus on enterprise-wide knowledge sharing and access," Dusty Tenney, PerkinElmer's president of analytical sciences and laboratory services, said in a statement. "This acquisition successfully positions PerkinElmer as the only technology provider able to deploy an optimized ELN solution across a global customer's entire value chain, from research to manufacturing."

- read PerkinElmer's release
- here's the Boston Business Journal's report

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.